---
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286586334.md"
description: "Dare Bioscience shares are trading lower after the company reported worse-than-expected Q1 sales results."
datetime: "2026-05-15T15:01:45.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286586334.md)
  - [en](https://longbridge.com/en/news/286586334.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286586334.md)
---

# 

Dare Bioscience shares are trading lower after the company reported worse-than-expected Q1 sales results.

### Related Stocks

- [DARE.US](https://longbridge.com/en/quote/DARE.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)

## Related News & Research

- [Precigen Q1 revenue beats estimates on PAPZIMEOS launch](https://longbridge.com/en/news/286311056.md)
- [Genprex data shows gene therapy reverses hyperglycemia in T2D mice at ASGCT](https://longbridge.com/en/news/286414681.md)
- [Regenxbio's muscle disorder therapy meets main goal in late-stage study](https://longbridge.com/en/news/286406339.md)
- [US cancer clinics scramble to get experimental Revolution Medicines pancreatic cancer drug](https://longbridge.com/en/news/286394551.md)
- [Analyst Reiterates Buy on Corbus, Maintains $38 Price Target on CRB-701 Oncology Potential](https://longbridge.com/en/news/286284525.md)